RT Journal Article
SR Electronic
T1 G protein subunit gamma 4 expression has potential of detection, prediction, and therapeutic target for liver metastasis of gastric cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.14.20175034
DO 10.1101/2020.08.14.20175034
A1 Haruyoshi Tanaka
A1 Mitsuro Kanda
A1 Takashi Miwa
A1 Shinichi Umeda
A1 Koichi Sawaki
A1 Chie Tanaka
A1 Daisuke Kobayashi
A1 Masamichi Hayashi
A1 Suguru Yamada
A1 Goro Nakayama
A1 Masahiko Koike
A1 Yasuhiro Kodera
YR 2020
UL http://medrxiv.org/content/early/2020/08/16/2020.08.14.20175034.abstract
AB Liver metastasis of gastric cancer is the most common for hematogenous metastases and so fatal, that the identification of novel markers and targets for therapy are crucial. We conducted transcriptome analyses between synchronous liver metastasis, primary tumor, and adjacent tissues from four patients with metastasis confined to the liver to discover that GNG4 upregulated substantially in primary gastric cancer tissues. Quantitative RT-qPCR assay for 300 gastric cancer patients revealed that higher levels of GNG4 in primary cancer were associated with shorter overall survival and a higher risk of liver recurrence. The oncogenic phenotypes of GNG4 were determined by knockout and forced expression of GNG4. Tumor formation by GNG4 knockout cells was more strikingly attenuated in a liver metastasis mouse model compared with a subcutaneous model. GNG4 is a candidate for a therapeutic target for liver metastasis, and its expression may enable us to provide better disease monitoring for liver metastasis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Grant-in-Aid for Encouragement of Young Scientists (2017, B, 17K16538), the Japanese Society for Gastroenterological Carcinogenesis (2016), Nakayama Cancer Research Institute (2016), and the Yokoyama Foundation for Clinical Pharmacology (2016).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All informed consent for the use of clinical samples and data was obtained from all patients in written manners, consistent with the requirement Institutional Review Board at Nagoya University, Japan. All animal experiments were conducted consistent with the ARRIVE guidelines and were approved by the Animal Research Committee of Nagoya University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in the manuscript and supplemental data. All other data will be available as needed unless related to personal information.